1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Partners hit as Reata ends PhIII BEACON trial with bardoxolone in CKD

Abbott investors sent the company's stock down for the second day in a row after its partner Reata Pharmaceuticals said on 18 October that the private firm had terminated the Phase III BEACON clinical trial evaluating its antioxidant inflammation modulator (AIM) bardoxolone methyl (RTA 402) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes.

Abbott investors sent the company's stock down for the second day in a row after its partner Reata Pharmaceuticals said on 18 October that the private firm had terminated the Phase III BEACON clinical trial evaluating its antioxidant inflammation modulator (AIM) bardoxolone methyl (RTA 402) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes.

The trial's independent data monitoring committee (IDMC) recommended that Irving, Texas-based Reata - which has ex-US license deals with Abbott and Kyowa Hakko Kirin worth more than $1 billion for the AIM programme - stop the trial and discontinue treatment of enrolled patients "for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from Therapeutic Category

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.